TOP2A and prostate cancer: Previous studies have suggested that TOP2A was upregulated and indicative of poor prognosis in many malignancies including lung adenocarcinoma (Kou et al., 2020), gastric cancer (Cao et al., 2017), breast cancer (Zheng et al., 2016), and prostate cancer (de Resende et al., 2013), which is noteworthy.